ER/PRs and AR drive cell growth, proliferation and metastasis in malignancies such as breast cancer and prostate cancer, respectively, thus therapeutic interventions focusing on limiting oestrogen, progesterone or androgen production, or preventing steroid binding to their respective receptors, could be beneficial. Here, ESR1 is linked to breast cancer.